Bayer
Bayer Extends CEO Bill Anderson’s Contract; Sarepta C-Suite Turmoil
Bill Anderson; Bayer; CEO contract extension; company transformation; restructuring; Sarepta; C-suite changes; pharma industry
Bayer’s Lynkuet (elinzanetant) Wins First-in-World Approval in UK, Challenging Astellas’ Hot Flash Drug
Bayer; elinzanetant; Lynkuet; menopause; hot flashes; vasomotor symptoms; Astellas; non-hormonal therapy; MHRA approval; UK first approval
Bayer’s BlueRock Lays Off 50 Employees, Shuts Cambridge Labs in Streamlining Move
BlueRock Therapeutics; Bayer; layoffs; biotech; Cambridge research labs; cell therapy; streamlining; bemdaneprocel; OpCT-001; pharmaceutical industry
Forging the Future of Cell Therapy: Bayer and BlueRock’s Unique Journey
cell therapy; Bayer; BlueRock Therapeutics; Parkinson’s disease; bemdaneprocel; biotech partnerships; RMAT designation; Phase 3 trials; regenerative medicine
Bayer Restructuring Cuts 2,000 Jobs, Thins Management Layers in 2025
Bayer; restructuring; job cuts; management layers; layoffs; Frankfurt plant closure; pharmaceutical industry
A closer look at pharmas top patent losses in 2025
Legal patent, Expiration, function, Market, Indication of (contextual qualifier), competition, Impact food supplement, Sales – occupational activity, Bayer, 2025, patent cliff, Regeneron, 2023
Bayer Expects Pharma Sales Dip in 2025 Despite Upcoming Launches
Bayer, pharmaceutical sales, revenue decline, new drug launches, Xarelto patent expiration
Bayer Prepares for Critical Challenges Amid Xarelto Decline
Bayer, Xarelto, patent expirations, generic competition, pharmaceutical industry, earnings decline, strategic plans, JPM25
Regeneron and Bayer Achieve Phase III Success with High-Dose Eylea for Retinal Vein Occlusion, Paving Way for Label Expansion
Regeneron, Bayer, Eylea HD, Retinal Vein Occlusion (RVO), Macular Edema, Phase III Trial, Label Expansion, Biosimilar Competition
Bayer Secures Exclusive Rights to Aficamten in Japan Through Licensing Agreement with Cytokinetics
Bayer, Cytokinetics, Aficamten, Japan, Licensing Agreement, Hypertrophic Cardiomyopathy (HCM), Cardiac Myosin Inhibitor